Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. - Wikidata - awgldk - TriplyDB

Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models.

Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models.

http://www.wikidata.org/entity/Q40333367

about

Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis Role of Akt signaling in resistance to DNA-targeted therapy Chemoresistance and targeted therapies in ovarian and endometrial cancers Conditional drug screening shows that mitotic inhibitors induce AKT/PKB-insensitive apoptosis An integrative approach to identifying cancer chemoresistance-associated pathways Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy.CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion.Cellular responses to Cisplatin-induced DNA damage.Cisplatin in cancer therapy: molecular mechanisms of action Lipoplatin formulation review article.Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin‑resistant ovarian cancer.Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis.Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer.Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary Estrogen receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression Fucoxanthin enhances cisplatin-induced cytotoxicity via NFκB-mediated pathway and downregulates DNA repair gene expression in human hepatoma HepG2 cells.Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma.Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells Wilms' tumour suppressor gene 1 (WT1) is involved in the carcinogenesis of Lung cancer through interaction with PI3K/Akt pathway.mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells Therapeutic targets and new directions for antibodies developed for ovarian cancer.Phosphatidylinositol 3-kinase inhibition restores Ca2+ release defects and prolongs survival in myotubularin-deficient mice.Cisplatin associated with LY294002 increases cytotoxicity and induces changes in transcript profiles of glioblastoma cells.The effects of silencing of PI3K p85α on 5-FU-induced colorectal cancer cells apoptosis.Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells.The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells.PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells.New Insights into mTOR Signal Pathways in Ovarian-Related Diseases: Polycystic Ovary Syndrome and Ovarian Cancer Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects Activation of estrogen receptor α by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells.Everolimus following 5-aza-2-deoxycytidine is a promising therapy in paclitaxel-resistant clear cell carcinoma of the ovary.Combination of intensity modulated radiotherapy followed treatment with p38 MAPK activation inhibitor inhibits the proliferation of MCF-7 breast cancer cells.

P2860

Q26858839-B51292EC-972C-480D-BF76-78804D0D841E Q28066950-0DE5EEC6-CCA6-419A-A822-0696A12700EA Q28073246-C54EB002-1375-4989-96C2-694CE9734B1D Q33476900-3A14BB16-FD03-43B0-83C1-7001A73AA2B1 Q33853380-24B47B73-E08A-455C-8551-251A8B4624FA Q33888946-E9CBF14D-44B8-43C9-97BB-ED7FC7630BD2 Q34036441-D7C09382-6EDF-4F51-91A3-937A25199A78 Q34089685-EA7FD5CC-2FAA-49BF-AD3D-FC445E7AA166 Q34098163-23FC1C27-9BAB-4D3F-8B24-8AF5E3400331 Q34214923-4BE3A2C2-7844-4C65-8050-F6B635C1B171 Q34426894-CB9B713C-4985-46E6-AFA1-FFBECA358B67 Q34443762-9A924665-EB0E-48D3-9514-7C89669D18D0 Q34616626-2649A168-0D0F-45BB-909C-80EB486534E6 Q34810176-29F7ACCB-8D04-4666-A035-8120335EEF9E Q35434007-E5F9D41D-28C4-4468-9332-7BB7FB92F829 Q35484712-409785A1-AFBF-4F73-B967-E70FA21F3ED2 Q36586981-4DAAA5AD-DF85-4AC0-9AA2-AAA4252A3EC0 Q36742629-F086FAFF-9D23-4EE1-972D-A5A052DA7A14 Q37016007-D4C99ABB-3840-4C2C-846A-E8EEA9A12FB3 Q37301601-3D056C5F-2DB7-46DA-A5A2-DD7EA4DBA507 Q37322906-EA01652F-26E6-4F30-83CB-2BCE45BF5899 Q37346570-5900FBC0-0042-4886-A688-65EB9549CE4B Q37356540-DB8D0CFB-B7E8-41F4-805E-2AD72A5E8C5A Q37397674-840D526B-6415-4816-BE45-7C484EA694AC Q37515114-5C1DA06C-EA34-4490-B611-32616CA07688 Q39064313-617F1DF2-BE66-4B69-BDAD-4C432BEC4B31 Q39102953-DA7455F6-624E-4FFE-B8BB-B47FDFBD6544 Q39400141-FA7E6EDD-7BC8-4902-AFEC-C56D1933F5BB Q39989937-BF1D1073-B7FA-4995-8FEC-05301B27C956 Q41996097-FFE7869A-296B-427A-B706-C89ECB63F173 Q42108466-F7181B3C-C5F8-4154-AAED-F6FE8099C8BA Q42144129-E672A06B-3BCC-4C88-BCF0-AA2BF0AEE16E Q42575787-FA360A52-0523-4EDD-9826-778D7E8B1C56 Q46425884-FE9F16BA-93EF-4F47-8A4B-91814A58F1D4 Q48507192-71EEF403-3EAB-4667-B5E3-1D2A0664B5B4 Q48520322-8C254F15-8CC7-40BD-97DA-7301A5575EB9

P2860

Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models.

http://www.wikidata.org/entity/Q40333367

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Inhibition of phosphatidylinos ...... in vivo ovarian cancer models.

@en

type

label

Inhibition of phosphatidylinos ...... in vivo ovarian cancer models.

@en

prefLabel

Inhibition of phosphatidylinos ...... in vivo ovarian cancer models.

@en

P1433

Q40333367-F482ED80-BC41-4071-BAED-B40E93ACCA79

P1476

Q40333367-225849BD-63D4-41E5-9CA1-DEFA1EADCB2E

P2093

Q40333367-1476502D-2AC1-4CA7-8B7A-3CF8D28519EA

Q40333367-1CF7F489-41AD-46B4-AE56-38130C991748

Q40333367-47C1A16D-CF9F-4FF0-86F7-F65AE8931E23

Q40333367-4E2DEE81-8B13-4EF5-B2B1-E9CAF29E9DCE

Q40333367-704E1CFD-BC0D-40E5-A2A1-D5B42DE92A68

Q40333367-71BD75C2-FABC-42D4-983F-7E68ACAEEE88

Q40333367-81AD6E9B-03D4-4491-B01F-B700D9C4B290

Q40333367-A7162CB8-6A48-45BB-A1C1-AC869ED7BFE5

Q40333367-B96EE8C3-B38B-43F2-A7BF-7EBBBF827D49

Q40333367-CB5B2BB3-18C3-4E15-9FC3-81FA2FB1D662

P304

Q40333367-60393B79-5985-4190-BDE4-84CB3D1C055C

P31

Q40333367-830891B3-A9DD-4B1F-9BE0-0EDADB8856F4

P356

Q40333367-1DC762E1-A2EF-4865-9000-480ED1F951F3

P407

Q40333367-C49926B1-D880-49C6-BB65-FC8C9A0ABF56

P433

Q40333367-5043A004-3C24-4916-96CC-D396DFC23665

P478

Q40333367-8F8887DB-84D9-4827-972B-56402C5B54CB

P577

Q40333367-2EDE4B0A-BCAE-422C-B6A6-E698C40442E7

P5875

Q40333367-735D4522-D60E-4EE5-8600-C2D3A503972C

P698

Q40333367-BA2D91B9-43E5-4F40-A168-7F0F609B6F40

P356

P1433

P1476

Inhibition of phosphatidylinos ...... in vivo ovarian cancer models.

@en

P2093

Botao Du

http://www.w3.org/2001/XMLSchema#string

Hideki Igarashi

http://www.w3.org/2001/XMLSchema#string

Hirohisa Kurachi

http://www.w3.org/2001/XMLSchema#string

Ishida Gabriela Mirei

http://www.w3.org/2001/XMLSchema#string

Jun Kawagoe

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Takahashi

http://www.w3.org/2001/XMLSchema#string

Keiichi Tasaka

http://www.w3.org/2001/XMLSchema#string

Maki Saitoh

http://www.w3.org/2001/XMLSchema#string

Masahide Ohmichi

http://www.w3.org/2001/XMLSchema#string

Masakazu Doshida

http://www.w3.org/2001/XMLSchema#string

P304

1761-1769

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/EN.2005-1450

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

147

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7374678

http://www.w3.org/2001/XMLSchema#string

P698

16396982

http://www.w3.org/2001/XMLSchema#string